


CHEMICAL MODIFICATIONS OF KANAMYCIN A
 SYNTHESIS OF 4"-DEOXY AND 4"-EPI-HALOGENODEOXY KANAMYCIN A*

R. Albert, K. Dax, A. E. Stütz, and H. Weidmann[†]

Institute of Organic Chemistry, Technical University Graz, A-8010 Graz, Austria

Abstract: Stereospecific direct replacement with inversion of configuration of 4"-OH by halogen in kanamycin A. Hydrogenolysis.

Chemical modifications¹ in kanamycin A (1) have hitherto primarily focussed on the 6-aminodeoxy-D-glucose (X') part, found to be the predominant site of enzymatic deactivation. Except for the transformations at 6", alterations in the kanosamine (X") part are rather rare.^{2,3}




- 1: R=R'=R''=H; R'''=OH
- 2: R=Ac; R'=BOC; R''=OH; R'''=H
- 3: R=Ac; R'=BOC; R''=H; R'''=Cl
- 4: R=Ac; R'=BOC; R''=H; R'''=Br
- 5: R=Ac; R'=BOC; R''=H; R'''=I
- 6: R=Ac; R'=BOC; R''=R'''=H
- 8: R=R'=R''=H; R'''=Cl
- 9: R=R'=R''=H; R'''=Br
- 10: R=R'=R''=H; R'''=I
- 11: R=R'=R''=R'''=H

We recently described⁴, inter alia, a very effective preparation of 2',3',4',2'',6''-penta-O-acetyl-tetra-N-tert.-butyloxycarbonyl-kanamycin A (2) by O-4"→-6" acetyl migration. Reaction of 2 with

- a) triphenylphosphane / carbon tetrachloride⁵ yielded 2',3',4',2'',6''-penta-O-acetyl-tetra-N-tert.-butyloxycarbonyl-4"-epi-chloro-4"-deoxy-kanamycin A (3) [m.p. 150-155°(dec.), $[\alpha]_D^{20} +93^\circ$ (c=1, CHCl₃), R_f^6 0.70] in 86%.
- b) triphenylphosphane dibromide⁷ formed 2',3',4',2'',6''-penta-O-acetyl-tetra-N-tert.-butyloxycarbonyl-4"-epi-bromo-4"-deoxy-kanamycin A (4) [m.p. 140-145°(dec.), $[\alpha]_D^{20} +88^\circ$ (c=1.4, CHCl₃), R_f^6 0.70] in 82% yield.
- c) triphenyl phosphite / methyl iodide⁸ afforded 2',3',4',2'',6''-penta-O-acetyl-tetra-N-tert.-butyloxycarbonyl-4"-deoxy-4"-epi-iodo-kanamycin A (5) [m.p. 145-147°(dec.), $[\alpha]_D^{20} +90^\circ$ (c=2.4, CHCl₃), R_f^6 0.70] in 85% yield.

The synthesis of the corresponding fluoro derivative, obtained by a completely independent approach, will be published in a different context.

Hydrogenolysis of 5 in absol. ethanol employing Raney nickel (FLUKA 83440) in the presence of equimolar amounts of triethyl amine gave 95% of 2',3',4',2",6"-penta-O-acetyl-tetra-N-tert.-butyloxycarbonyl-4"-deoxy-kanamycin A (6) [m.p. 145-150° (dec.), $[\alpha]_D^{20} +75^\circ$ (c=1, CHCl₃), R_f^6 0.55]. Attempts to use 3, 4 or 5 as sub-



strates for displacement reactions with a variety of nucleophiles in order to obtain 4"-modified kanamycins, invariably resulted in elimination with quantitative formation of 2',3',4',2",6"-penta-O-acetyl-tetra-N-tert.-butyloxycarbonyl-4"-deoxy-4"-eno-kanamycin A (7) [m.p. 130-135°, $[\alpha]_D^{20} +100^\circ$ (c=3, CHCl₃), R_f^6 0.56, ¹³C-NMR: C-4" 99.3, C-5" 152.4].

Compounds 3, 4, 5, and 6 were subjected to Zemplén de-O-acetylation followed by treatment with trifluoroacetic acid to give the deprotected kanamycin A derivatives, which were purified by gradient elution with ammonia from Amberlite CG 50 [NH₄⁺]:

4"-epi-chloro-4"-deoxy-kanamycin A (8), $[\alpha]_D^{20} +149^\circ$ (c=3, H₂O), R_f^9 0.70;
¹³C-NMR¹⁰: C-3" 53.8 (54.4), C-4" 64.0 (60.8).

4"-epi-bromo-4"-deoxy-kanamycin A (9), $[\alpha]_D^{20} +137^\circ$ (c=1, H₂O), R_f^9 0.70;
¹³C-NMR¹⁰: C-3" 53.6 (54.2), C-4" 62.7 (54.2).

4"-epi-iodo-4"-deoxy-kanamycin A (10), $[\alpha]_D^{20} +107^\circ$ (c=1, H₂O), R_f^9 0.70;
¹³C-NMR¹⁰: C-3" 53.6 (54.2), C-4" 47.0 (34.9).

4"-deoxy-kanamycin A (11), $[\alpha]_D^{20} +133^\circ$ (c=1, H₂O), R_f^9 0.58;
¹³C-NMR¹⁰: C-3" 50.4 (51.4), C-4" 39.9 (32.4).

Compared to kanamycin A, all compounds described exhibit a reduced antibiotic activity.

Acknowledgement: Financial support by the Fonds zur Förderung der wissenschaftlichen Forschung, project 3471, as well as biological screening by Sandoz Forschungsinstitut, Vienna, is gratefully acknowledged.

Notes and references:

- * Presented at the 1st European Symposium on Carbohydrates and Glycoconjugates, Vienna, September 14 - 17, 1981.
- 1 J. Reden and W. Dürckheimer, *Top. Curr. Chem.*, **83**, 138 (1979) and references cited therein.
- 2 S. Inouye, *Chem. Pharm. Bull.*, **15**, 1888 (1967).
- 3 T. Miyasaka, D. Ikeda, S. Kondo, and H. Umezawa, *J. Antibiot.*, **33**, 527 (1980).
- 4 R. Albert, K. Dax, A. E. Stütz, and H. Weidmann, *J. Carbohydr. Chem.*, in press.
- 5 R. Appel and H.-D. Wihler, *Chem. Ber.*, **109**, 3446 (1976).
- 6 Merck 5554, toluene/ethyl acetate 1:2 (v/v); starting material 2: R_f 0.52.
- 7 L. Horner, H. Oediger, and H. Hoffmann, *Liebigs Ann. Chem.*, **626**, 26 (1959).
- 8 N. K. Kochetkov and A. I. Usov, *Tetrahedron*, 973 (1963).
- 9 Merck 5554, CHCl₃/CH₃OH/NH₄OH(25%) 1:2:2 (v/v/v); kanamycin A (1): R_f 0.51.
- 10 Bruker WH 90; D₂O; shifts after acidification (pD <2) with DCl in parentheses; kanamycin A (1): C-3" 57.2 (58.0), C-4" 72.3 (66.7).